MORAb-066 Phase 1 Study (Completed)
This study was a Phase 1, first-in-human, dose-escalation study of MORAb-066, an investigational humanized immunoglobulin G (IgG) monoclonal antibody (mAb) that targets tissue factor (TF) expressing malignancies, such as breast, pancreatic, colorectal, and non-small-cell lung cancer (NSCLC) (adenocarcinoma). This open-label study assessed the safety, tolerability, and pharmacokinetics of MORAb-066 administered weekly.
For more information, visit ClinicalTrials.gov. (Identifier: NCT01761240)
For more information about MORAb-066, please click here.
The information contained herein is investigational and is not intended to make claims of safety or efficacy prior to approval by the FDA or other regulatory authorities. There is no guarantee that the agents described or their uses will be approved by the FDA or other regulatory authorities.